Experiments with breast cancer cells harboring mutations in the LBD-encoding region of the ESR1 gene have shown that mutant cells require a higher anti-estrogen drug concentration and that they proliferate in an estradiol-independent manner through constitutive activation of the ER pathway1. This evidence concerns the gene ESR1 and breast carcinoma.